Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry - Report - MDSpire

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

  • By

  • Hyungwoo Cho

  • Koji Kato

  • Jason Yongsheng Chan

  • Kim Dajung

  • Haiwen Huang

  • Qingqing Cai

  • Tongyu Lin

  • Udomsak Bunworasate

  • Sen-Mui Tan

  • Ka-Won Kang

  • Jae-Yong Kwak

  • Tsai-Yun Chen

  • Jeong-Ok Lee

  • Seong Hyun Jeong

  • Young Rok Do

  • Esther Chan

  • Hye Jin Kang

  • Hyeon-Seok Eom

  • Sung Yong Oh

  • Youngil Koh

  • Hyo Jung Kim

  • Se-Hyung Kim

  • Jong Ho Won

  • Young Hoon Park

  • Deok Hwan Yang

  • Soo Chin Ng

  • Jae-Cheol Jo

  • Hilman Tadjoedin

  • Anna Mira Lubis

  • Noorwati Sutandyo

  • Tsuyoshi Muta

  • Ken Takase

  • Dok Hyun Yoon

  • Won Seog Kim

  • May 29, 2026

  • 0 min

Share

Clinical Report: Advancements in Treatment and Survival Outcomes of Consolidation Therapies for Mantle Cell Lymphoma

Overview

This study evaluates real-world treatment patterns and survival outcomes in newly diagnosed mantle cell lymphoma (MCL) patients across the Asia-Pacific region. Key findings include the impact of upfront autologous stem cell transplantation (ASCT) and rituximab maintenance therapy on progression-free survival (PFS) and overall survival (OS).

Background

Mantle cell lymphoma (MCL) is a subtype of B-cell lymphoma with varying treatment strategies based on patient characteristics. Despite extensive research in Western populations, there is a lack of comprehensive data from the Asia-Pacific region. Understanding treatment patterns and outcomes in this demographic is crucial for optimizing care.

Data Highlights

MeasureOverall CohortASCT GroupNo ASCT Group
5-year PFS63.8%45.1%
5-year OS88.3%63.8%

Key Findings

  • Median age at diagnosis was 62 years, with 75.1% male patients.
  • 86.8% of patients received rituximab-based regimens as first-line therapy.
  • Upfront ASCT utilization increased from 13.8% in 2013 to 40.0% in 2020.
  • 5-year PFS for ASCT patients was 63.8% compared to 45.1% for those without ASCT.
  • 5-year OS for ASCT patients was 88.3% compared to 63.8% for those without ASCT.
  • Rituximab maintenance therapy was administered to 12.1% of eligible patients.

Clinical Implications

The findings highlight the importance of upfront ASCT in improving survival outcomes for younger MCL patients. Clinicians should consider patient age and response to first-line therapy when determining treatment strategies.

Conclusion

This study provides valuable insights into the treatment landscape of MCL in the Asia-Pacific region, emphasizing the benefits of ASCT and the evolving role of rituximab maintenance therapy.

Related Resources & Content

  1. The ASCO Post, 2024 -- Addition of Ibrutinib to Immunochemotherapy and ASCT Improves Survival in Mantle Cell Lymphoma
  2. The ASCO Post, 2019 -- Local Consolidative Therapy Linked to Survival Benefit in Oligometastatic Non–Small Cell Lung Cancer
  3. Blood Cancer Journal, 2023 -- Changing Treatment Approaches and Enhanced Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma
  4. EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma, 2025
  5. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma, 2024
  6. Blood Cancer Journal — Analysis of Treatment Approaches and Patient Outcomes in Primary Mediastinal Large B-Cell Lymphoma: Insights from a Swedish Lymphoma Registry
  7. EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - The European Hematology Association (EHA)
  8. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network - ScienceDirect
  9. A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphoma | Blood Research | Springer Nature Link

Original Source(s)

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

  • by Hyungwoo Cho, Koji Kato, Jason Yongsheng Chan, Kim Dajung, Haiwen Huang, Qingqing Cai, Tongyu Lin, Udomsak Bunworasate, Sen-Mui Tan, Ka-Won Kang, Jae-Yong Kwak, Tsai-Yun Chen, Jeong-Ok Lee, Seong Hyun Jeong, Young Rok Do, Esther Chan, Hye Jin Kang, Hyeon-Seok Eom, Sung Yong Oh, Youngil Koh, Hyo Jung Kim, Se-Hyung Kim, Jong Ho Won, Young Hoon Park, Deok Hwan Yang, Soo Chin Ng, Jae-Cheol Jo, Hilman Tadjoedin, Anna Mira Lubis, Noorwati Sutandyo, Tsuyoshi Muta, Ken Takase, Dok Hyun Yoon, Won Seog Kim

  • May 29, 2026

Related Content

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

Biotech exec Jeremy Levin on the industry’s strategic turning point